TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04411355

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control by dietitian

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programs
Description: In line with the address information of the intervention patients, purpose/content of the study was discussed with the gyms of municipalities and patients were made to benefit from these facilities for free. For the patients preferring private gyms, it was ensured that discounts were made for the patients.
Study: NCT04380246

Intervention type: OTHER
Intervention: Qualitative Interview
Description: There is no intervention as part of this study. Clinicians will participate in a qualitative interview.
Study: NCT04411355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: control by psychiatrist
Description: The psychiatrist assessed the suitability of the patients to the study, assessed the patients having adaptation problems with respect to lifestyle changes in monthly controls and also played roles in teaching the coping methods to patients and applying and interpreting the hospital anxiety and depression scale.
Study: NCT01425151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-Gel
Description: Oropharyngeal leak pressure Insertion success

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSeal
Description: Oropharyngeal leak pressure Insertion success
Study: NCT03303794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivacaine
Description: 0.25% bupivacaine in patients undergoing total knee arthroplasty

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Description: 0.25% bupivacaine in patients undergoing total knee arthroplasty
Study: NCT02965807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty
Description: patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
Study: NCT02970292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken as two tablets, once daily by mouth
Study: NCT00832559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Description: 1, 3 or 6 doses of CAVATAK (10\^9 TCID50) at 48 hour intervals.
Study: NCT01797575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-cysteine (NAC)
Description: taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl-cysteine (NAC)
Description: taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
Study: NCT04041284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Monthly 225 mg subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT04096196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe City game
Description: The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
Study: NCT00757250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
Study: NCT01478035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
Study: NCT01437774

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy (ReStore or Merci)
Description: Each arm will use either ReStore or Merci as the primary thrombectomy device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thrombectomy (ReStore or Merci)
Description: Each arm will use either ReStore or Merci as the primary thrombectomy device
Study: NCT03809611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNR844-Cl
Description: 1.5% Ophthalmic solution for topical ocular administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02803021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - SR15-47-Z13-076)
Study: NCT00713427

Intervention type: DEVICE
Group type: OTHER
Intervention: WallFlex™ Biliary Partially-Covered Stent
Description: Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
Study: NCT03730155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCT intervention.
Description: 8-week course with 2 hours sessions weekly. Participants should meditate 25 min. pr. day during the 8 weeks.
Study: NCT01232829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Description: Given PO
Study: NCT06258070

Intervention type: OTHER
Group type: OTHER
Intervention: Abobotulinumtoxin A injection for bruxism
Description: Trigger points were detected with careful palpating of the masticatory muscles (masseter and temporalis muscles) of patients suffering from bruxism. Each trigger point received 0,05 lm ol reconstituted solution of Abobotulinumtoxin A. Dysport (Ipsen Pharma, Germany) was reconstituted with 0.9% sodium chloride solution so that 0.1 ml corresponded to 25 U.
Study: NCT02223260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran
Description: Experimental dose chosen based on age and weight
Study: NCT00236977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer
Description: iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: oral iron tablets; 325 mg three times a day orally for 56 days
Study: NCT00749996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAM™ Spinal Stabilization System
Description: The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Herniectomy
Description: Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments.
Study: NCT03711500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
Study: NCT01801956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: free membership of a sport club

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interview
Description: Four motivational interviews by instructors of the local sport club

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: Four motivational interviews by instructors of the local sport club

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual arena
Description: Uploading of training data from a GPS-watch to a virtual arena
Study: NCT04015895

Intervention type: OTHER
Intervention: DEFCO tool
Description: The Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system DEFCO tool is questionnaire to identify their social vulnerabilities. A neural network instantly identifies the patient's fragility and sends the result by email to the professionals identified in the organization of each center. These professionals then relay to the social workers in order to take care of the patient's fragility.
Study: NCT04505241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely-delivered physical activity promotion
Description: Over video-call, participants will receive educational content on safely increasing their levels of physical activity (e.g., selecting an appropriate form of exercise, minimizing health risks, the importance of planning), will receive daily text messages (see arm descriptions) for six weeks and complete a 10-15 minute check-in call at the 3-week point of the intervention to assess compliance with daily step goals as well as to help problem-solve barriers to compliance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely-delivered physical activity promotion
Description: Over video-call, participants will receive educational content on safely increasing their levels of physical activity (e.g., selecting an appropriate form of exercise, minimizing health risks, the importance of planning), will receive daily text messages (see arm descriptions) for six weeks and complete a 10-15 minute check-in call at the 3-week point of the intervention to assess compliance with daily step goals as well as to help problem-solve barriers to compliance.
Study: NCT04138485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: 10% liquid formulation of human immunoglobulin for IVIG

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5% human albumin solution stabilized with 250 mmol/L L-proline
Study: NCT04933929

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post-hospitalization nutritional monitoring
Description: Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs \& Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-hospitalization nutritional monitoring
Description: Post-hospitalization nutritional monitoring, carried out by dieticians from Saveurs \& Vie. Consultations are done remotely, by phone only. Dietitians have gained experience in home nutritional monitoring of elderly people over the phone during the first wave of Coronavirus disease 2019 (COVID-19) .
Study: NCT00264706

Intervention type: DRUG
Group type: OTHER
Intervention: Nona-L-arginine
Study: NCT00586209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Glutamine
Description: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (\>66.7 kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
Study: NCT00578682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Single IV dose of 3 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Single IV dose of 15 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Single IV dose of 30 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-557
Description: Single IV dose of 0.3 mg/kg
Study: NCT01732809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AbobotulinumtoxinA (ABO)
Description: Isovolumetric (0.02 mL) doses of 2 units of abobotulinumtoxinA injected on one side of the forehead.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA (ONA)
Description: Isovolumetric (0.02 mL) doses of 2 units of onabotulinumtoxinA injected on the other side of the forehead.
Study: NCT04609852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E8001
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E8001
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E8001
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E8001
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion.
Study: NCT03106623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-8577
Description: Oral administration of ONO-8577 once a daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin succinate + mirabegron
Description: Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of Placebo once a daily for 4 weeks
Study: NCT05058833

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiographic grades of diastolic function was defined according to 2016 ASE/EACVI recommendations for the evaluation of LV diastolic function. Cardiac diastolic dysfunction was defined as elevated E/e'≥15.

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary flow reserve and index of microcirculatory dysfunction
Description: Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary flow reserve and index of microcirculatory dysfunction
Description: Coronary microcirculatory dysfunction was defined as having both depressed CFR (≤2.0) and elevated IMR (≥23U).
Study: NCT02071407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.~Morphine can be used to supply adequate analgesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02370615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam syrup.
Study: NCT00835237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: Intramuscular, single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Decavac™
Description: Intramuscular, single dose.
Study: NCT04467307

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigit bronchoscopy
Description: After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigit bronchoscopy
Description: After general anesthesia, the airway is checked with a rigid bronchoscope suitable for the age. If there is a foreign body, it is removed by forceps.
Study: NCT03339921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections for chronic compartment syndrome
Description: Botulinum toxin will be injected in the upper and lower portion of the affected area with a syringe

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical fasciotomy for chronic compartment syndrome
Description: linear incisions will be made into the affected compartment releasing the underlying fascial layer, reducing the pressure of the compartment
Study: NCT01171846

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle training
Description: Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).~Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation.
Study: NCT00486408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef
Description: 1.5x10\^10 Ad vg
Study: NCT04650373

Intervention type: PROCEDURE
Intervention: Bariateric surgery
Description: Adult patients underwent RYGB surgical treatment during the period from 2014 to 2019
Study: NCT00075504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Given IV
Study: NCT05946369

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to lymphocyte ratio
Description: Complete blood count with differential to evaluate the Neutrophil to lymphocyte ratio for each patient

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to lymphocyte ratio
Description: Complete blood count with differential to evaluate the Neutrophil to lymphocyte ratio for each patient